ACT-AD Activities

ACT-AD and our members conduct activities throughout the year to focus attention on the need to accelerate cures and treatments for Alzheimer's disease.

November 30, 2010
ACT-AD, together with the Alzheimer's Federation of America, and the Alzheimers Drug Discovery Foundation, will host a workshop that will bring together researchers, clinicians, regulators, drug developers and advocacy groups to discuss challenges in recent Alzheimer’s disease drug development and explore novel approaches to improving the way in which Phase II trials for disease-modifying therapies are designed in the future.

July 11, 2010
The 13th Annual International Conference on Alzheimer’s Disease (ICAD) took place in Honolulu, Hawaii from July 9 to July 15, 2010.  At this conference, Alzheimer’s experts from around the world gathered to discuss significant breakthroughs in the field of Alzheimer’s research and present results from clinical trials of potential AD therapies.  The ACT-AD Coalition had a presence in Honolulu during the conference.

On July 11, ACT-AD sponsored an informal meeting of leading Alzheimer’s experts from the U.S. and Europe.  The meeting provided an opportunity for these experts to share their insights into how the development and evaluation of novel AD therapies could be improved.  ACT-AD and its members were recognized during this meeting for the work they do to help move the Alzheimer’s field forward on scientific issues that affect the way new therapies are developed and reviewed, as well as to provide forums where thought leaders can present possible solutions to regulators.

September 24, 2009
ACT-AD commissioned a voter sentiment survey to gauge American’s attitudes towards Alzheimer’s disease, the importance they place on finding a cure for the disease, and what policies they would support to ease the burden of the disease on patients and caregivers. Key findings will be presented on September, 24, 2009 at the Rockstars of Science briefing on Capitol Hill.
View Full Survey Data
View Key Findings
View Press Release
View Alzheimer's Research Forum article about the survey
View Rockstars of Science Agenda

July 21, 2009
ACT-AD, together with the Alzheimer's Association and LEAD (Leaders Engaged in Alzheimer's Disease), hosted a scientific workshop to stimulate an open discussion with FDA officials, scientists, drug developers, academics and advocacy organizations on standards of clinical meaningfulness and exploring novel approaches regarding the state of the science in this vital field. The workshop was a public event and held on July 21, 2009 from 8:00am to 12:30pm at the Hilton Rockville Executive Meeting Center in Rockville, MD.
View Press Release

May 14, 2008
ACT-AD chairman Daniel Perry participated in a panel presentation at Dialogue on Diversity's 2008 Health Care Symposium.
View Slides

March 31, 2008
ACT-AD Members Urge House and Senate Appropriations Subcommittee Chairs to Increase Funds for FDA Drug Review Activities in FY 2009.
Read Letter

March 13, 2008
ACT-AD, together with the Alzheimer's Association and the Alzheimer's Study Group, hosts a scientific workshop to stimulate an open discussion with FDA leadership on the subject of clinical meaningfulness in new AD therapies and help advance the dialogue regarding how best to measure the clinical effectiveness of emerging therapies.
See Press Release : Read Alzheimer Research Forum Article

November 13, 2007
Alzheimer's Foundation's J. Weeson Op-Ed on Alzheimer's screening is published in the Sacramento Bee
Read Op-Ed

November 2, 2007
Congressman Tom Latham's holds a roundtable discussion on aging and Alzheimer’s disease with Dr. Molly Wagster, Ph.D.,  Dan Perry and Stephen McConnell. Wagster is Chief of the Behavioral and Systems Neuroscience Branch of the Neuroscience and Neuropsychology of Aging Program at the National Institute on Aging (NIA), a branch of the National Institutes of Health (NIH). Perry is the Executive Director of the not-for-profit Alliance for Aging Research. McConnell is the Vice President for Advocacy and Public Policy at the Alzheimer’s Association.
Watch and listen to the discussion

October 17, 2007
FDA convenes a meeting of neurological disease advocacy and research organizations focused on constructive engagement in the area of Alzheimer's disease and other neurological disease.
See Russell Katz' presentation (PDF)
See Dr. Celia Witten's presentation (PDF)

September 27, 2007
ACT-AD hosts a member summit in Washington, DC to recap progress the coalition has made in 2007 and showcase planned activities for 2008.
See speaker presentation (PDF)

July 25, 2007
Avalere Health holds an audio conference to discuss the ACT-AD-sponsored study on the way the FDA reviews potential Alzheimer's disease, HIV/AIDS, and cancer therapies.
See speaker presentation (PDF)

June 5, 2007
An ACT-AD-sponsored study by Avalere Health reveals differences in the way the FDA reviews potential Alzheimer's disease, HIV/AIDS, and cancer therapies.
See Press Release (PDF)

April 25, 2007
ACT-AD submits letters to House and Senate subcommittees that handle FDA appropriations outlining FDA's need for more resources to review promising AD therapies.

May 14, 2007
ACT-AD press briefing to release study of first economic projection of social value of treatments that delay onset of Alzheimer's Disease.
See Press Release (PDF)
Read Report (PDF)
Speaker Bios (PDF)

April 27, 2006
First major study of Baby Boomer Attitudes on Alzheimer's released by ACT-AD.
Read survey results (PDF)
See press release (PDF)